Table 1 Comprehensive in vitro pharmacology profile of TRP601
From: Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor
Non-peptide receptors | Peptide receptors | Nuclear receptors |
|---|---|---|
Adenosine | Angiotensin-II | Glucocorticoid |
Adrenergic | Bombesin | Estrogen alpha |
Cannabinoid | Calcitonin gene-related peptide | Androgen |
Dopamine | Chemokine | |
GABA | Cholecystokinin | Ion channels |
Glutamate | Complement 5a | Ca2+ channels |
Glycine | Endothelin | K+ channels |
Histamine | Galanin | Na+ channel |
Imidazole | Glucagon | |
Leukotriene | Growth hormone secretagogue | Enzymes |
Melatonin | Melanin-concentrating hormone | Kinases |
Muscarinic | Motilin | Phosphatases |
Nicotinic | Neurokinin | Serine proteases |
Purinergic | Neuropeptide Y | Cysteine proteases |
Serotonin | Neurotensin | Aspartate proteases |
Sigma | Opioid and opioid-like | Arachidonic acid metabolism |
Somatostatin | Prostaglandin metabolism | |
Amine transporters | Thyroid hormone | Monoamine synthesis and metabolism |
Choline | Urotensin-II | Neurotransmitter synthesis and metab. |
Dopamine | Vasoactive intestinal peptide | Nitric oxide synthesis |
GABA | Rolipram | Second messenger systems |
Norepinephrine | Vasopressin | ATPases |
Seretonin | Lipid synthesis | |
Metalloproteases | ||
Miscellaneous enzymes |
